Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

Condition:   Salivary Gland Cancer
Interventions:   Drug: Nivolumab;   Drug: Ipilimumab
Sponsors:   Memorial Sloan Kettering Cancer Center;   Bristol-Myers Squibb
Recruiting - verified May 2017

http://ift.tt/2qF3uOv